The law firm Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether the company issued materially misleading business information to the investing public.
This follows the filing of a securities class action lawsuit against Beta Bionics. The lawsuit alleges that the company made false and/or misleading statements and failed to disclose that there were material weaknesses in its internal controls over financial reporting related to revenue recognition.
Investors who purchased Beta Bionics common stock pursuant to the company's initial public offering in November 2024 or between November 7, 2024, and February 24, 2026, have until May 20, 2026, to seek appointment as lead plaintiff in the case. Faruqi & Faruqi has not yet filed a lawsuit and there has been no determination of liability.
Beta Bionics is a medical technology company focused on the development and commercialization of the iLet Bionic Pancreas System, an automated insulin delivery device for people with diabetes.
